Is Vaginal Estrogen Safe? Painful Sex, Dryness and What Changed on the Label
Low-dose vaginal estrogen treats the dryness and painful sex of menopause, and in two large cohorts users had no higher risk of heart disease, stroke or cancer. In 2026 the FDA approved a vaginal estrogen label without the old boxed warning. Breast cancer survivors should decide with their oncologist.
By Kymata Health Editorial Published Last checked
We earn a commission if you buy through links on this page. It never changes our grades or rankings. How we make money →
This guide
Women's Libido & Hormones- Question
- Is low-dose vaginal estrogen safe, including after breast cancer?
- Sources
- 8 cited
- Quick answers
- 3 questions
- Clinician review
- None; sources cited inline
Key takeaways
5 points- Genitourinary syndrome of menopause (dryness, irritation and painful sex caused by falling estrogen) affects an estimated 27% to 84% of postmenopausal women, and low-dose vaginal estrogen is an effective treatment for moderate to severe symptoms1.
- In two large NIH-funded cohorts, women using vaginal estrogen had no higher risk of heart disease, stroke, blood clots or cancer than non-users34.
- In February 2026 the FDA approved labels that remove heart disease, breast cancer and dementia from the boxed warning of menopausal hormone products, including one vaginal estrogen6; the updated Estring label has no boxed warning7.
- A progestogen is not needed with low-dose vaginal estrogen, but endometrial safety has not been studied in trials beyond 1 year1.
- After breast cancer, NAMS says the data are insufficient and the decision should involve your oncologist1.
What vaginal estrogen treats
Genitourinary syndrome of menopause (GSM), which includes vaginal dryness and atrophy, can impair sexual function and quality of life, and The North American Menopause Society (NAMS) says it is likely underdiagnosed and undertreated. Over-the-counter lubricants and moisturizers are enough for most women with mild symptoms; for moderate to severe symptoms, low-dose vaginal estrogen, vaginal DHEA, systemic estrogen and ospemifene are effective1.
A Cochrane review of 30 trials (6,235 women) found low-quality evidence that vaginal creams, tablets and rings improve symptoms compared with placebo, with no evidence of a difference between them2.
Pain with sex is a different problem from low desire. If desire itself is the issue, see our low libido guide; the vaginal DHEA insert is covered in our DHEA guide.
Cancer, heart disease and blood clots
In the Women's Health Initiative Observational Study, 45,663 women aged 50 to 79 who were not using systemic estrogen were followed for a median of 7.2 years. Among women with a uterus, vaginal estrogen users had no significant difference in stroke, invasive breast cancer, colorectal or endometrial cancer, or blood clots, and lower rates of coronary heart disease, fracture and death from any cause. The study was funded by the National Institutes of Health3.
In the Nurses' Health Study, followed for 18 years, risks of cardiovascular disease, cancer and hip fracture did not differ between users and non-users of vaginal estrogen, and no outcome was significantly increased; the study is also NIH-funded4.
Both are observational studies, so they show associations rather than proof: women who choose vaginal estrogen may differ in other ways from those who do not.
Do you need progesterone?
NAMS says a progestogen is not indicated with low-dose vaginal estrogen, but that endometrial safety has not been studied in clinical trials beyond 1 year1. In the Cochrane review, estrogen cream was linked to more endometrial thickening than the ring, possibly because of the higher cream doses used2.
Absorption is low but not zero: about 8% of the estradiol the Estring ring releases each day reaches the bloodstream unchanged. Its label tells clinicians to investigate persistent or recurring abnormal bleeding in women with a uterus, including endometrial sampling when indicated7.
What changed on the label in 2026
In November 2025 the FDA began removing risk statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning of menopausal hormone therapy products. On February 12, 2026 it approved the first six updated labels, covering each category of hormone therapy, including topical vaginal estrogen6. Our boxed warning explainer covers the change.
The updated Estring label has no boxed warning. It still lists contraindications, and it says systemic exposure is generally lower than with systemic estrogens and that the relevance of their risks to Estring is not known7.
Labels are being updated product by product. When we checked FDA's Drugs@FDA site on October 14, 2026, the most recent Vagifem label posted there (revised February 2024) still carried the older boxed warning and listed breast cancer or a history of breast cancer as a contraindication8. Read the leaflet that comes with your product.
After breast cancer
NAMS says there are insufficient data to confirm the safety of vaginal estrogen in women with breast cancer, and that treatment should consider the woman's needs and her oncologist's recommendations1.
A 2024 study of 49,237 women with breast cancer in Scotland and Wales found that 5% used vaginal estrogen after diagnosis, and users had no higher risk of dying from breast cancer than women who used no hormone therapy (hazard ratio 0.77). It was observational, and its authors reported grant funding from Cancer Research UK and other public bodies5.
Who should avoid it, and when to see a clinician
The Estring label lists these contraindications and warnings7. For online prescribing options, see vaginal estrogen online.
- Abnormal genital bleeding that has not been diagnosed7.
- Known or suspected estrogen-dependent cancer7; breast cancer survivors should decide with their oncologist1.
- Active or past blood clots (DVT or pulmonary embolism), or active or past stroke or heart attack7.
- Liver disease, or a known clotting disorder such as protein C, protein S or antithrombin deficiency7.
- Pregnancy: the label says Estring should not be used during pregnancy7.
- See a clinician promptly for any vaginal bleeding after menopause, which the label calls a possible warning sign of cancer of the uterus7.
- Ring users: toxic shock syndrome has been reported with vaginal rings; warning signs include fever, vomiting, diarrhea, muscle pain, dizziness, faintness or a sunburn-like rash7.
Where to buy
Gala
Paid links · we earn a commissionOnline hormone care for women. Its hormone page (checked Oct 14, 2026) lists vaginal estradiol cream or tablet for dryness and painful intercourse, alongside estradiol pills or patches and progesterone, prescribed by a US-licensed clinician after an online assessment. Eligibility is decided at intake, and breast cancer survivors should involve their oncologist.
See Gala's HRT plans (paid link, opens in new tab)
Quick answers
Questions
3 answersIs vaginal estrogen the same as HRT?
It is a form of hormone therapy, but much less reaches the bloodstream: about 8% of the estradiol Estring releases each day is absorbed unchanged7. NAMS says a progestogen is not indicated with low-dose vaginal estrogen1.
Does vaginal estrogen raise breast cancer risk?
In two large cohorts, users had no higher risk of invasive breast cancer than non-users34. If you have had breast cancer, NAMS says the data are insufficient and your oncologist should be involved1.
Does vaginal estrogen help low libido?
It treats dryness and pain, which can impair sexual function1. Low desire itself is a separate diagnosis; see our low libido guide.
More in Women's Libido & Hormones
Keep reading
6 pages- Women's Libido & Hormones hubEvery guide, regulatory notes and sources
- Low Libido in Women: Causes, When It's HSDD, and the Treatments With Trial Data
- DHEA for Women: Libido, Menopause and Side Effects, Oral Pills vs the Vaginal Insert
- Estrogen Dominance: What's Real, What's Marketing, and What to Ask Your Doctor Instead
- Does Birth Control Lower Your Sex Drive? What the Trials Show
- Addyi vs Vyleesi: Pill or Injection for Low Libido, and How Well Each Works
Keep reading: Menopause and HRT
Menopause and HRT: every pageWomen's hormone telehealth comparedBrowse all topics
- Previous in this topicAddyi vs Vyleesi: Pill or Injection for Low Libido, and How Well Each WorksAddyi is a nightly pill for women under 65; Vyleesi is an as-needed injection for premenopausal women only.
- Next in this topicWaking at 3 a.m. in perimenopause: what is happening and what helpsWhy women in perimenopause wake at 3 a.m.
- Progesterone in HRT: Micronized vs SyntheticIf you have a uterus and take systemic estrogen, you need a progestogen to protect the uterine lining: in the PEPI trial, estrogen alone caused endometrial hyperplasia that the…
- Vaginal Health: Bacterial Vaginosis, Yeast Infections and Probiotics, by the EvidenceBacterial vaginosis came back within a year in more than half of women in one study, and a 2025 trial found treating male partners too cut recurrence.
- Red CloverRed clover is a meadow legume whose flower-top extracts, rich in isoflavones, are sold mainly for menopausal hot flashes.
References
Every study and document cited in this guide, numbered as in the text.
Sources
8 sources- 1The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause, 2020. PMID 32852449
- 2Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev, 2016. PMID 27577677
- 3Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause, 2018. PMID 28816933
- 4Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. Menopause, 2018. PMID 30562320
- 5Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol, 2024. PMID 37917089
- 6FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. U.S. Food and Drug Administration, 2026.
- 7ESTRING (estradiol vaginal system): prescribing information (2026). U.S. Food and Drug Administration, 2026.
- 8Vagifem (estradiol vaginal inserts): prescribing information (revised 02/2024). U.S. Food and Drug Administration, 2024.
Dietary supplements are not intended to diagnose, treat, cure or prevent any disease, and these statements have not been evaluated by the FDA. Prescription options need a licensed clinician. Talk to your clinician or pharmacist before starting anything new, especially if you take prescription medicines, are pregnant or breastfeeding.